Author

Nicola Thompson

Wellcome Sanger InstituteORCID 0000-0003-0527-0096Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Assay:CRISPR screen· 1 Approach:experimental assay· 1 Approach:machine learning (classical)· 1

Frequent Co-Authors

David J. AdamsiD· 2 shared Aida Shahrabi· 1 shared Anneliese O. SpeakiD· 1 shared Anton Enright· 1 shared Antonia Pritchard· 1 shared Barbara De KegeliD· 1 shared Chi Wong· 1 shared Clara AlsinetiD· 1 shared

Activity by Year

2017-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersSystems Biology

David J. AdamsORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Systems BiologyCell SystemsPeer-reviewedSep 15, 2021

Comprehensive prediction of robust synthetic lethality between paralog pairs in cancer cell lines

Barbara De Kegel, Niall Quinn, Nicola Thompson…·Colm J. Ryan

The paper predicts synthetic lethal interactions between paralog pairs in cancer cell lines using machine learning and features from CRISPR screens and molecular profiles.

68 citationstop 4%

humanCRISPR screen

𝕏 PostBluesky

Cancer BiologybioRxivPreprintSep 28, 2017

A screen for combination therapies in BRAF/NRAS wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combination

Marco Ranzani, Kristel Kemper, Magali Michaut…·David J. Adams

DOI 10.1101/195354

humanbulk RNA-seq

𝕏 PostBluesky